
Amelia McCartney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7377484/publications.pdf Version: 2024-02-01



AMELIA MCCADTNEY

#	Article	IF	CITATIONS
1	COVIDâ€19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 570-577.	1.1	24
2	Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers Journal of Clinical Oncology, 2022, 40, 648-648.	1.6	0
3	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51.	2.8	8
4	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. Cancer Research, 2022, 82, OT1-02-02-OT1-02-02.	0.9	0
5	250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation. Annals of Oncology, 2022, 33, S223.	1.2	2
6	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. Vaccines, 2022, 10, 851.	4.4	15
7	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136.	7.7	25
8	Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial. , 2021, , .		4
9	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Research, 2021, 23, 38.	5.0	14
10	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 4687.	4.1	23
11	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials Journal of Clinical Oncology, 2021, 39, 1038-1038.	1.6	16
12	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers, 2021, 13, 2762.	3.7	14
13	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncology, The, 2021, 22, e327-e340.	10.7	121
14	A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer. Clinical Breast Cancer, 2021, 21, e332-e339.	2.4	3
15	Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults. JAMA Oncology, 2020, 6, 204.	7.1	2
16	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3574.	3.7	42
17	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Research, 2020, 22, 83.	5.0	6
18	The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer. JAMA Oncology, 2020, 6, 1535.	7.1	10

AMELIA MCCARTNEY

#	Article	IF	CITATIONS
19	Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. British Journal of Cancer, 2020, 123, 176-177.	6.4	4
20	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139.	7.0	40
21	Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?. Chinese Clinical Oncology, 2020, 9, 42-42.	1.2	Ο
22	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. Biomarkers in Medicine, 2020, 14, 495-498.	1.4	3
23	Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , .		Ο
24	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666.	2.8	113
25	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. Breast Journal, 2019, 25, 1225-1229.	1.0	0
26	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. Npj Breast Cancer, 2019, 5, 26.	5.2	12
27	Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer. Breast, 2019, 44, S11.	2.2	1
28	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews, 2019, 74, 29-34.	7.7	23
29	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	2.4	12
30	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research, 2019, 21, 71.	5.0	19
31	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer, 2019, 114, 55-66.	2.8	30
32	LEPTOMENINGEAL DISEASE: AN UPDATE. Breast, 2019, 48, S28-S29.	2.2	0
33	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. Cancers, 2019, 11, 1894.	3.7	53
34	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	3.2	3
35	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. Breast, 2019, 48, S81-S84.	2.2	1
36	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		0

#	Article	IF	CITATIONS
37	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		Ο
38	Metabolomics in breast cancer: A decade in review. Cancer Treatment Reviews, 2018, 67, 88-96.	7.7	87
39	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 329-341.	2.5	17
40	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	3.2	5
41	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Research, 2018, 38, 4839-4845.	1.1	5
42	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	3.2	14
43	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Annals of Oncology, 2018, 29, 1748-1754.	1.2	76
44	Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial Journal of Clinical Oncology, 2018, 36, 12031-12031.	1.6	1
45	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06) Journal of Clinical Oncology, 2018, 36, 570-570.	1.6	0
46	Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?. Oncotarget, 2018, 9, 34031-34032.	1.8	0
47	Systemic Treatment of Metastatic Breast Cancer (MBC) in Older Adults. Breast, 2017, 36, S24.	2.2	Ο
48	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. Breast, 2017, 34, S13-S18.	2.2	6
49	Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients. Annals of Oncology, 2017, 28, v25-v26.	1.2	О